deltatrials
Completed PHASE1/PHASE2 INTERVENTIONAL 1-arm NCT00416351

Clofarabine in Treating Patients With T-Cell or Natural Killer-Cell Non-Hodgkin's Lymphoma That Has Relapsed or Not Responded to Previous Treatment

A Phase I/II Study of Clofarabine in Patients With Relapsed T-Cell and NK-Cell Lymphomas

Sponsor: Memorial Sloan Kettering Cancer Center

Conditions Leukemia Lymphoma Small Intestine Cancer
Interventions clofarabine
Updated 11 times since 2017 Last updated: Apr 25, 2022 Started: Jun 27, 2006 Primary completion: Mar 1, 2021 Completion: Mar 1, 2021
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00416351, this PHASE1/PHASE2 trial focuses on Leukemia and Lymphoma and remains completed. Sponsored by Memorial Sloan Kettering Cancer Center, it has been updated 11 times since 2006, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshotActive Not Recruiting~Feb 2017 – ~Jun 2018 · 16 months · monthly snapshotActive Not Recruiting~Jun 2018 – ~Sep 2018 · 3 months · monthly snapshotActive Not Recruiting~Sep 2018 – ~Sep 2019 · 12 months · monthly snapshotActive Not Recruiting~Sep 2019 – ~Sep 2020 · 12 months · monthly snapshotActive Not Recruiting~Sep 2020 – ~Jan 2021 · 4 months · monthly snapshotActive Not Recruiting~Jan 2021 – ~Apr 2021 · 3 months · monthly snapshotActive Not Recruiting~Apr 2021 – ~Jun 2022 · 14 months · monthly snapshotCompleted~Jun 2022 – ~Jul 2024 · 25 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – present · 21 months · monthly snapshotCompleted

Change History

11 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE1/PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  3. Jun 2022 — Jul 2024 [monthly]

    Completed PHASE1_PHASE2

  4. Apr 2021 — Jun 2022 [monthly]

    Completed PHASE1_PHASE2

    Status: Active Not Recruiting → Completed

  5. Jan 2021 — Apr 2021 [monthly]

    Active Not Recruiting PHASE1_PHASE2

▶ Show 6 earlier versions

  1. Sep 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  2. Sep 2019 — Sep 2020 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  3. Sep 2018 — Sep 2019 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  4. Jun 2018 — Sep 2018 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  5. Feb 2017 — Jun 2018 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  6. Jan 2017 — Feb 2017 [monthly]

    Active Not Recruiting PHASE1_PHASE2

    First recorded

Jun 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Memorial Sloan Kettering Cancer Center
  • National Cancer Institute (NCI)
  • The Cleveland Clinic
  • University of Rochester
Data source: Memorial Sloan Kettering Cancer Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations